Nestle weight-loss foods will be released to the public very soon. The company plans to release food options and food products catered to support those who are on the GLP-1 medication diet or the Wegovy or Ozempic users.
Nestle is launching a new line of high-fiber, protein-packed foods aimed at the growing number of Americans on these types of medication as well as those pursuing weight loss goals.
The Swiss food and beverage giant unveiled this innovative range, called Vital Pursuit, on Tuesday, emphasizing its suitability for a balanced diet and portion alignment for consumers using semaglutide medications.
Nestle's Weight-Loss Foods Meet Diverse Health Needs
The new Vital Pursuit line will feature twelve distinct food items, including whole grain bowls, sandwich melts, and pizzas.
These products are set to arrive in select stores across the United States by the end of this year.
Nestle USA Meals Division President Tom Moe highlighted that the new line of goods produced by the company is important to cater to the different individualized health needs of their consumers.
"We know that every consumer on a health journey has individualized needs and considerations, and having options to support those needs will continue to play an important role," Moe stated.
Nestle's strategic move coincides with the increasing popularity of GLP-1 medications for weight management in the changing landscape of health and fitness nationwide.
Initially prescribed for Type 2 diabetes management due to their blood sugar regulation capabilities, medications such as Ozempic, Mounjaro, Wegovy, and Zepbound also effectively reduce appetite by signaling to the brain that the stomach is full.
This appetite suppression has sparked concern among food retailers about potential impacts on their sales.
The Rising Demand for GLP-1 Medications Nationwide
Data from analytics firm Trilliant Health revealed that around 9 million prescriptions for GLP-1 medications were written in the fourth quarter of 2022.
Projections from JPMorgan estimate that the number of GLP-1 users will reach 30 million by 2030, with the market value exceeding $100 billion.
Additionally, Morgan Stanley Research analysts predict that by 2035, 24 million Americans, or 7% of the U.S. population, will be using these medications.
Nestle North America CEO Steve Presley sees the increasing use of GLP-1 medications as an opportunity. "As more Americans take GLP-1 medications, Nestle executives see an opportunity to serve those consumers," Presley commented.
Broader Market Response
Nestle is not alone in recognizing this market potential. Other companies are also launching products tailored to GLP-1 medication users.
Vegan meal delivery service Daily Harvest introduced a GLP-1-friendly line of 15 foods in January, offering a $20-per-day, five-day meal plan. Abbott Laboratories has similarly entered the market with a protein-rich drink designed for GLP-1 users.
Nestle, known for brands like DiGiorno pizza and Stouffer's frozen meals, plans to price each item in the Vital Pursuit line at $4.99, although retailers may adjust this price.
This new line is part of a broader strategy by Nestle to attract weight-conscious consumers. CEO Mark Schneider mentioned during an earnings briefing last year that the company is also developing supplements to ensure those on GLP-1 medications receive necessary vitamins and nutrients despite lower calorie intake.
